IGFL3 Inhibitors
IGFL3 Inhibitors encompass a diverse array of chemical compounds that target various signaling pathways potentially linked to IGFL3's functional activity. For instance, inhibitors such as Gefitinib and WZ4002 that target the EGFR tyrosine kinase can indirectly diminish the activity of IGFL3 by blocking the PI3K/AKT pathway, a key conduit for numerous growth factors and regulatory proteins. These compounds prevent phosphorylation events that would normally propagate survival and proliferation signals downstream of EGFR, signals that IGFL3 might use to exert its effects on cellular processes. Similarly, Triciribine's targeted inhibition of AKT activation would stifle the cellular responses that IGFL3 may influence through the PI3K/AKT signaling axis.
In the context of the MAPK pathway, U0126 and Sorafenib serve as inhibitors of MEK and RAF kinase, respectively. These small molecules obstruct the MAPK/ERK signaling cascade, which could be a critical mediator of IGFL3's downstream effects. Inhibition by U0126 and Sorafenib would result in a dampened cellular response to IGFL3 engagement, assuming IGFL3 acts upstream of these kinases. Furthermore, compounds like SP600125 and BMS-345541, which inhibit JNK and NF-kappaB pathways respectively, could suppress the potential pro-inflammatory or pro-survival roles of IGFL3. By blocking these pathways, the chemicals could prevent the transcriptional activation of genes that might be upregulated in response toIGFL3 function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
An EGFR tyrosine kinase inhibitor that can inhibit downstream signaling pathways such as PI3K/AKT, which are implicated in cell survival and proliferation. Blocking this pathway can indirectly inhibit IGFL3 by reducing the survival signals that IGFL3 may rely upon for its function. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
A specific AKT inhibitor that prevents AKT phosphorylation and activation. Since IGFL3 is predicted to act upstream of AKT, inhibiting AKT would decrease the functional output of IGFL3 signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A MEK inhibitor that blocks the MAPK/ERK pathway. If IGFL3 functions through this pathway, U0126 would inhibit the downstream effects of IGFL3 by preventing ERK activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which is part of the MAPK signaling pathways. By inhibiting JNK, SP600125 can indirectly diminish the functional activity of IGFL3 if JNK is downstream of IGFL3 action. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that can attenuate the PI3K/AKT pathway, potentially reducing IGFL3 signaling if IGFL3 utilizes this pathway for transmitting its cellular effects. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can suppress the mTORC1 complex, which is downstream of PI3K/AKT. Inhibition of mTORC1 by Rapamycin could indirectly lessen IGFL3's functional activity if it is involved in this pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A RAF kinase inhibitor that also targets VEGFR and PDGFR. By inhibiting RAF kinase, Sorafenib can inhibit MAPK/ERK signaling, possibly reducing IGFL3 activity if it signals through these kinases. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A Src family kinase inhibitor that can inhibit multiple downstream signaling pathways, including those involved in cell migration and proliferation. This could indirectly reduce IGFL3 function if IGFL3 signaling is mediated through Src family kinases. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
An inhibitor of the TGF-beta type I receptor ALK5, which blocks the TGF-beta/Smad signaling pathway. This inhibition could indirectly affect IGFL3 if its function is linked to TGF-beta signaling. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
An EGFR inhibitor that targets mutant forms and spares wild-type EGFR. This selective inhibition can affect downstream signaling pathways that may indirectly influence IGFL3 activity. | ||||||